
Could Venetoclax Improve Outcomes of CAR T for Patients with Resistant B-Cell Lymphomas? New Insights at ASH
Could Venetoclax Improve Outcomes of CAR T for Patients with Resistant B-Cell Lymphomas? New Insights at ASH
Details
More Products & Services
People

Kimberly Sweeney
Roswell Park Comprehensive Cancer Center
Vice President of Patient Experience

Sai Yendamuri
Roswell Park Comprehensive Cancer Center
Chief Strategy Officer; SVP of Business Development & Outreach; Chair of Thoracic Surgery

Shashi Lele
Roswell Park Comprehensive Cancer Center
Medical Director, International Patients

Sunita Panesar
Roswell Park Comprehensive Cancer Center
Vice President of Strategy, Business Development & Outreach
Description
HIGHLIGHTS:
- Standard therapies prove ineffective for a third of patients with DLBCL
- Roswell Park team studying whether Bcl-2-inhibiting drug may enhance CAR T
- Underlying mechanism hinges on calcium signaling, scientists reveal
- Standard therapies prove ineffective for a third of patients with DLBCL
- Roswell Park team studying whether Bcl-2-inhibiting drug may enhance CAR T
- Underlying mechanism hinges on calcium signaling, scientists reveal

Share
Recent Chats
Share via email
Future: handle WhatsApp here
Future: handle LinkedIn here
Future: handle Twitter here
SUBMENU HERE
Share via Chat
Copy Link